SMMT Summit Therapeutics Inc

Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, will be announcing its financial results for the second quarter and half year ended 31 July 2016 on Thursday, 8 September 2016. 

Summit will host a conference call the same day at 1:00pm BST / 8:00am EDT. Conference call information will be included in the half year results press release and a replay of the call will also be available through the Company's website, www.summitplc.com.

About Summit Therapeutics Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease DMD and the infectious disease Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

For more information, please contact:

Summit Therapeutics
Glyn Edwards / Richard Pye (UK office)		Tel: +44 (0)1235 443 951
Erik Ostrowski / Michelle Avery (US office)		+1 617 225 4455
Cairn Financial Advisers LLP
(Nominated Adviser)
Liam Murray / Tony Rawlinson		Tel: +44 (0)20 7148 7900
N+1 Singer
(Broker)
Aubrey Powell / Jen Boorer		Tel: +44 (0)20 7496 3000
MacDougall Biomedical Communications
(US media contact)		Tel: +1 781 235 3060
Chris Erdman / Karen Sharma		cerdman@macbiocom.com /
		ksharma@macbiocom.com
Consilium Strategic Communications
(Financial public relations, UK)		Tel: +44 (0)20 3709 5700
Mary-Jane Elliott / Sue Stuart /		summit@consilium-comms.com
Jessica Hodgson / Lindsey Neville